Open in app

Efgartigimod's safety, effectiveness and tolerance in individuals with generalized myasthenia gravis.

img-1
Total Views:
61
img-1
Total Likes:
4
img-1
Published By:
Peeyush Ghalot
img-1
Published On:
12-03-2022
(Image Courtesy: - Seek Alpha)

Efgartigimod alfa is a novel type of medicine that blocks Fc receptors in new borns. It's a fragment of an antibody that binds to the neonatal Fc receptor (FcRn) and prevents it from recycling immunoglobulin G (IgG) back into the bloodstream. The medicine lowers total IgG levels, including aberrant acetylcholine receptor (AChR) antibodies found in people with myasthenia gravis. In December 2021, it received FDA approval for medicinal usage in the United States. There is an unmet need for effective, tailored, well-tolerated therapeutic alternatives for generalized myasthenia gravis that may be employed in a wide range of patients. In patients with generalized myasthenia gravis, we wanted to see if Efgartigimod (ARGX-113), a human IgG1 antibody Fc fragment designed to lower pathogenic IgG autoantibody levels, was safe and effective. In individuals with generalized myasthenia gravis, efgartigimod was well tolerated and effective. Individualized dosage based on clinical response was a unique element of ADAPT, and the current open-label extension will help to guide translation to clinical practice with longer-term safety and effectiveness data.

Reference: - https://pubmed.ncbi.nlm.nih.gov/34146511/